ReviewOncogene2004
Effects of the leukemia-associated AML1-ETO protein on hematopoietic stem and progenitor cells.
Review in Oncogene, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 56 citations in OpenAlex.
- Article
- Different roles of E proteins in t(8;21) leukemia: E2-2 compromises the function of AETFC and negatively regulates leukemogenesis.Proceedings of the National Academy of Sciences of the United States of America · 2019Article
- Article
- Epigenetic Regulators in the Development, Maintenance, and Therapeutic Targeting of Acute Myeloid Leukemia.Frontiers in oncology · 2018Review
- Article
- Caspase-3 controls AML1-ETO-driven leukemogenesis via autophagy modulation in a ULK1-dependent manner.Blood · 2017Article
- C/EBPβ regulates homeostatic and oncogenic gastric cell proliferation.Journal of molecular medicine (Berlin, Germany) · 2016Article
- TLE4 regulation of wnt-mediated inflammation underlies its role as a tumor suppressor in myeloid leukemia.Leukemia research · 2016Article
- Discovery of progenitor cell signatures by time-series synexpression analysis during Drosophila embryonic cell immortalization.Proceedings of the National Academy of Sciences of the United States of America · 2015Article
- JMJD1C is required for the survival of acute myeloid leukemia by functioning as a coactivator for key transcription factors.Genes & development · 2015Article
- Article
- Copy number genome alterations are associated with treatment response and outcome in relapsed childhood ETV6/RUNX1-positive acute lymphoblastic leukemia.Haematologica · 2014Article
- The rate of spontaneous mutations in human myeloid cells.Mutation research · 2013Article
- Long and short non-coding RNAs as regulators of hematopoietic differentiation.International journal of molecular sciences · 2013Review
- Article
- AML1-ETO driven acute leukemia: insights into pathogenesis and potential therapeutic approaches.Frontiers of medicine · 2012Review
- The leukemia associated nuclear corepressor ETO homologue genes MTG16 and MTGR1 are regulated differently in hematopoietic cells.BMC molecular biology · 2012Article
- Contribution of an aged microenvironment to aging-associated myeloproliferative disease.PloS one · 2012Article
- The leukemogenicity of AML1-ETO is dependent on site-specific lysine acetylation.Science (New York, N.Y.) · 2011Article
- Array-based genomic resequencing of human leukemia.Oncogene · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Insights into the pathogenesis of human leukemia have relied heavily on studies of the identified chromosomal translocations found in this group of malignant diseases. Acquired, balanced translocations in acute myelogenous leukemia (AML) generally involve transcriptional regulatory genes, whereas in the myeloproliferative disorders tyrosine kinases are frequently involved. These rearrangements alter the function of at least one and often both of the involved genes. In this review, we focus on the AML1-ETO (a.k.a. RUNX1-ETO) fusion protein, which is found in t(8;21)+ AML. Expression of AML1-ETO in human hematopoietic stem cells (HSCs) preferentially enhances their maintenance, as opposed to their differentiation. The direct effects of AML1-ETO on human and murine HSCs, and the potentially cooperating events that may contribute to its leukemogenic properties, are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.